Ensysce BiosciencesENSCW 23 3-Year ROIIC % is -320.44 as of Dec. 2025. GuruFocus rates ENSCW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 1,324 Biotechnology companies, Ensysce Biosciences ranks worse than 84.37% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Ensysce Biosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -320.44%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Ensysce Biosciences's 3-Year ROIIC % or its related term are showing as below:
ENSCW's 3-Year ROIIC % is ranked worse than 84.37% of 1324
companies
in the Biotechnology industry
Industry Median: -4.42
vs ENSCW: -320.44
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Ensysce Biosciences 3-Year ROIIC % Related Terms
Ensysce Biosciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Ensysce Biosciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENSCW vs RNAZ, ALZN, CELZ: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Ensysce Biosciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensysce Biosciences 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Ensysce Biosciences's 3-Year ROIIC % falls into.
Ensysce Biosciences's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -10.241 (Dec. 2025) - -24.222 (Dec. 2022) )
/
( 0.517 (Dec. 2025) - 4.88 (Dec. 2022) )
=
13.981
/
-4.363
=
-320.44%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Ensysce Biosciences (ENSCW) has a 3-Year ROIIC % of -320.44 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ensysce Biosciences and its competitors. According to the industry distribution chart, Ensysce Biosciences ranks #1117 out of 1324 companies in the Biotechnology industry, placing it in the top 84.4%.
Is Ensysce Biosciences' 3-Year ROIIC % too high?
Ensysce Biosciences' current 3-Year ROIIC % is -320.44. Based on the distribution chart, Ensysce Biosciences ranks #1117 out of 1324 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ensysce Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ensysce Biosciences' 3-Year ROIIC % compare to RNAZ and ALZN?
According to the Biotechnology industry distribution chart, Ensysce Biosciences ranks #1117 out of 1324 companies for 3-Year ROIIC %. This places Ensysce Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ensysce Biosciences and its competitors. Ensysce Biosciences's current 3-Year ROIIC % is -320.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ensysce Biosciences stock overvalued right now?
Ensysce Biosciences (ENSCW) has a current 3-Year ROIIC % of -320.44. The current 3-Year ROIIC % is -320.44. Ensysce Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Ensysce Biosciences (ENSCW), the current 3-Year ROIIC % is -320.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score
Get the complete analysis for ENSCW
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENSCW has been successfully added to your 
